STOCK TITAN

[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4

Sutro Biopharma (STRO) reported an insider purchase on Form 4. CFO Gregory K. Chow bought 19,750 shares of common stock on 10/15/2025 with transaction code P (purchase). The weighted average price was $0.81, with individual trades executed between $0.8099 and $0.8100. Following the transaction, he beneficially owned 19,750 shares, held directly.

Sutro Biopharma (STRO) ha riportato un'acquisto da insider tramite Form 4. Il CFO Gregory K. Chow ha acquistato 19.750 azioni di azioni ordinarie il 15/10/2025 con il codice di transazione P (acquisto). Il prezzo medio ponderato è stato di 0,81 USD, con operazioni singole eseguite tra 0,8099 USD e 0,8100 USD. A seguito della transazione, deteneva 19.750 azioni, possedute direttamente.

Sutro Biopharma (STRO) informó de una compra de insider en el Formulario 4. El CFO Gregory K. Chow compró 19.750 acciones de acciones ordinarias el 15/10/2025 con código de transacción P (compra). El precio medio ponderado fue de $0.81, con operaciones individuales ejecutadas entre $0.8099 y $0.8100. Después de la transacción, poseía de forma beneficiosa 19.750 acciones, poseídas directamente.

Sutro Biopharma (STRO)가 Form 4에서 내부자 매수를 보고했습니다. CFO Gregory K. Chow가 19,750주의 보통주를 P 거래코드로 매수했습니다. 2025-10-15일에 매수했습니다. 가중 평균가는 $0.81였고 개별 거래는 $0.8099$0.8100 사이에 실행되었습니다. 거래 후 그는 19,750주직접 보유한 수익자(beneficial owner)로 남아 있습니다.

Sutro Biopharma (STRO) a signalé un achat d'initié sur le formulaire 4. Le directeur financier Gregory K. Chow a acheté 19 750 actions ordinaires le 15/10/2025 avec le code de transaction P (achat). Le prix moyen pondéré était de 0,81 USD, les transactions individuelles ayant été exécutées entre 0,8099 USD et 0,8100 USD. Suite à la transaction, il possédait 19 750 actions, en propriété bénéficiaire et détenues directement.

Sutro Biopharma (STRO) meldete einen Insider-Kauf auf Formular 4. CFO Gregory K. Chow kaufte am 15.10.2025 19.750 Aktien Stammaktien mit dem Transaktionscode P (Kauf). Der gewichtete Durchschnittspreis betrug 0,81 USD, wobei einzelne Trades zwischen 0,8099 USD und 0,8100 USD durchgeführt wurden. Nach der Transaktion besaß er 19.750 Aktien in wirtschaftlichem Eigentum, direkt gehalten.

Sutro Biopharma (STRO) أبلغت عن شراء من الداخل على النموذج 4. اشترى المدير المالي Gregory K. Chow 19,750 سهماً من الأسهم العادية في 15/10/2025 مع رمز المعاملة P (شراء). كان السعر المتوسط المرجّح $0.81، مع تنفيذ صفقات فردية بين $0.8099 و $0.8100. عقب الصفقة، كان يمتلك 19,750 سهماً، مباشرةً.

Sutro Biopharma (STRO) 在表格4上报告内部人士交易。CFO Gregory K. Chow 于 2025-10-15 购买了 19,750 股普通股,交易代码为 P(买入)。加权平均价格为 $0.81,单笔交易价格在 $0.8099$0.8100 之间。交易完成后,他以受益所有人身份直接持有 19,750 股

Positive
  • None.
Negative
  • None.

Sutro Biopharma (STRO) ha riportato un'acquisto da insider tramite Form 4. Il CFO Gregory K. Chow ha acquistato 19.750 azioni di azioni ordinarie il 15/10/2025 con il codice di transazione P (acquisto). Il prezzo medio ponderato è stato di 0,81 USD, con operazioni singole eseguite tra 0,8099 USD e 0,8100 USD. A seguito della transazione, deteneva 19.750 azioni, possedute direttamente.

Sutro Biopharma (STRO) informó de una compra de insider en el Formulario 4. El CFO Gregory K. Chow compró 19.750 acciones de acciones ordinarias el 15/10/2025 con código de transacción P (compra). El precio medio ponderado fue de $0.81, con operaciones individuales ejecutadas entre $0.8099 y $0.8100. Después de la transacción, poseía de forma beneficiosa 19.750 acciones, poseídas directamente.

Sutro Biopharma (STRO)가 Form 4에서 내부자 매수를 보고했습니다. CFO Gregory K. Chow가 19,750주의 보통주를 P 거래코드로 매수했습니다. 2025-10-15일에 매수했습니다. 가중 평균가는 $0.81였고 개별 거래는 $0.8099$0.8100 사이에 실행되었습니다. 거래 후 그는 19,750주직접 보유한 수익자(beneficial owner)로 남아 있습니다.

Sutro Biopharma (STRO) a signalé un achat d'initié sur le formulaire 4. Le directeur financier Gregory K. Chow a acheté 19 750 actions ordinaires le 15/10/2025 avec le code de transaction P (achat). Le prix moyen pondéré était de 0,81 USD, les transactions individuelles ayant été exécutées entre 0,8099 USD et 0,8100 USD. Suite à la transaction, il possédait 19 750 actions, en propriété bénéficiaire et détenues directement.

Sutro Biopharma (STRO) meldete einen Insider-Kauf auf Formular 4. CFO Gregory K. Chow kaufte am 15.10.2025 19.750 Aktien Stammaktien mit dem Transaktionscode P (Kauf). Der gewichtete Durchschnittspreis betrug 0,81 USD, wobei einzelne Trades zwischen 0,8099 USD und 0,8100 USD durchgeführt wurden. Nach der Transaktion besaß er 19.750 Aktien in wirtschaftlichem Eigentum, direkt gehalten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chow Gregory K.

(Last) (First) (Middle)
C/O SUTRO BIOPHARMA, INC.
111 OYSTER POINT BOULEVARD

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SUTRO BIOPHARMA, INC. [ STRO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 P 19,750 A $0.81(1) 19,750 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8099 to $0.8100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ David Pauling as attorney-in-fact for Gregory K. Chow 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did STRO report?

A Form 4 reporting that CFO Gregory K. Chow purchased 19,750 common shares on 10/15/2025.

How many STRO shares were bought and at what price?

19,750 shares at a weighted average price of $0.81, with trades between $0.8099 and $0.8100.

What is the transaction code for the STRO insider trade?

Code P, which indicates a purchase.

How many STRO shares does the insider own after the trade?

19,750 shares beneficially owned directly following the reported transaction.

Who is the reporting person in this STRO Form 4?

Gregory K. Chow, Chief Financial Officer.

On what date did the STRO insider transaction occur?

10/15/2025.

Does the filing provide price detail for each trade?

It provides a weighted average and a $0.8099–$0.8100 range, with a note offering full breakdown upon request.

Sutro Biopharma

NASDAQ:STRO

STRO Rankings

STRO Latest News

STRO Latest SEC Filings

STRO Stock Data

74.66M
80.88M
4.6%
62.93%
3.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO